REVELATION BIOSCIENCES, INC. - 8-K Filing
Revelation Biosciences reported a net loss of $3.0 million for the three months ended March 31, 2026, or $2.71 per share, compared to a net loss of $2.1 million ($25.34 per share) in the same period in 2025. The company had $14.1 million in cash and equivalents as of March 31, up from $10.7 million at year-end due to $6.7 million in net proceeds from a January warrant inducement. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $REVB